Atezolizumab
MSS
Replimune, Inc.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the MSS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | B |
Irinotecan Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | B |
Cetuximab Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | B |
Nivolumab Pfizer | Phase 2 | B |
Ipilimumab Pfizer | Phase 2 | B |
View all 20 →
Same molecule, other indications
Atezolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →